Lichter Jay 4
4 · Janux Therapeutics, Inc. · Filed Jun 16, 2021
Insider Transaction Report
Form 4
Lichter Jay
Director10% Owner
Transactions
- Conversion
Series Seed Convertible Preferred Stock
2021-06-15−888,888→ 0 total(indirect: See footnote)→ Common Stock (1,138,665 underlying) - Conversion
Series B Convertible Preferred Stock
2021-06-15−900,264→ 0 total(indirect: See footnote)→ Common Stock (1,153,238 underlying) - Conversion
Common Stock
2021-06-15+674,211→ 4,387,217 total(indirect: See footnote) - Conversion
Common Stock
2021-06-15+2,696,843→ 2,696,843 total(indirect: See footnote) - Conversion
Series A Convertible Preferred Stock
2021-06-15−526,316→ 0 total(indirect: See footnote)→ Common Stock (674,211 underlying) - Conversion
Common Stock
2021-06-15+1,138,665→ 1,330,815 total(indirect: See footnote) - Conversion
Common Stock
2021-06-15+2,382,191→ 3,713,006 total(indirect: See footnote) - Conversion
Common Stock
2021-06-15+1,153,238→ 3,850,081 total(indirect: See footnote) - Purchase
Common Stock
2021-06-15$17.00/sh+629,411$10,699,987→ 4,479,492 total(indirect: See footnote) - Conversion
Series Seed 2 Convertible Preferred Stock
2021-06-15−1,859,634→ 0 total(indirect: See footnote)→ Common Stock (2,382,191 underlying) - Conversion
Series A Convertible Preferred Stock
2021-06-15−2,105,264→ 0 total(indirect: See footnote)→ Common Stock (2,696,843 underlying)
Footnotes (4)
- [F1]Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- [F2]The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. Dr. Lichter disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any.
- [F3]The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter shares voting and investment power with respect to the shares held by ABV SPV. Dr. Lichter disclaims beneficial ownership of all shares held by ABV SPV except to the extent of his actual pecuniary interest therein, if any.
- [F4]The shares were purchased in the Issuer's initial public offering.